Inici › Càncer de pròstata › Illinois › Chicago
Assaigs clínics de Càncer de pròstata a Chicago, IL
45 estudis de Càncer de pròstata busquen participants en centres de Chicago i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
ReclutantFase 3
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
ReclutantFase 3
- Northwestern University, Chicago
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
ReclutantFase 1
- University of Chicago Hospital, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ReclutantEstudi observacionalVoluntaris sans benvinguts
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- i 1 més
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
ReclutantFase 2
- University of Illinois Cancer Center, Chicago
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
ReclutantFase 2
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
ReclutantFase 2/3
- University of Chicago, Chicago
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
ReclutantFase 3
- University of Illinois Chicago, Chicago
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
ReclutantFase 3
- Northwestern University, Chicago
- University of Illinois Cancer Center at Chicago, Chicago
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
ReclutantFase 3
- Research Site, Chicago
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
ReclutantFase 3
- Rush University Medical Center-Hematology and Oncology ( Site 0028), Chicago
- University of Illinois at Chicago-University of Illinois Cancer Center ( Site 0063), Chicago
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
ReclutantFase 3
- Northwestern University, Chicago
- University of Illinois, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
ReclutantFase 1
- University of Illinois Hospital & Health Sciences System, Chicago
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
Reclutant
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
ReclutantFase 2
- University of Chicago Comprehensive Cancer Center, Chicago
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
ReclutantFase 2
- Jesse Brown VA Medical Center, Chicago, IL, Chicago
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
ReclutantFase 1/2
- University of Chicago, Chicago
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
ReclutantFase 3
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
ReclutantFase 1
- University of Chicago Medical Center, Chicago
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
ReclutantFase 1/2
- Research Site, Chicago
PSMA PET Combined With MRI for the Detection of PCa
ReclutantFase 3Voluntaris sans benvinguts
- UroPartners,LLC, Chicago
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
ReclutantFase 3
- Rush MD Anderson, Chicago
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
ReclutantFase 3
- University of Illinois, Chicago
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
ReclutantFase 2
- Northwestern University, Chicago
rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
ReclutantFase 1 inicialVoluntaris sans benvinguts
- Northwestern University, Chicago
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
ReclutantFase 2
- UChicago Medicine Comprehensive Cancer Center, Chicago
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
ReclutantEstudi observacional
- University of Illinois at Chicago, Chicago
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- University of Chicago, Chicago
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
ReclutantEstudi observacionalVoluntaris sans benvinguts
- Northwestern, Chicago
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
ReclutantFase 1
- Research Site, Chicago
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
ReclutantFase 1/2
- Rush University, Chicago
Clinical Trial of Approaches to Prostate Cancer Surgery
Reclutant
- Northwestern University, Chicago
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
ReclutantFase 2
- Northwestern University, Chicago
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
ReclutantFase 1/2
- University of Chicago Medical Center, Chicago
Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life
Reclutant
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
GU-01: Glycyrrhizin in Prostate Cancer
ReclutantFase 2
- University of Illinois, Chicago
PSMA PET for Surveillance After Focal Therapy
Reclutant
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
ReclutantFase 1
- The University of Chicago Comprehensive Cancer Center, Chicago
Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)
ReclutantEstudi observacional
- The University of Chicago, Hyde Park · a 5 mi
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
ReclutantFase 3
- Northwestern University, Chicago
- University of Illinois, Chicago
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
ReclutantFase 4
- University of Chicago Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutantEstudi observacional
- Massive Bio SYNERGY-AI site, Chicago
Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
Reclutant
- The University of Illinois at Chicago (UIC), Chicago
- UChicago Medicine Comprehensive Cancer Center, Chicago
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
ReclutantFase 3
- Rush University Medical Center, Chicago
- University of Illinois, Chicago
Geriatric Assessment and Technology Evaluation in Prostate Cancer
ReclutantEstudi observacional
- o University of Chicago Medicine Comprehensive Cancer Center, Chicago
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
ReclutantFase 4
- University of Chicago Medical Center, Chicago
Assaigs de Càncer de pròstata en altres ciutats
- New York City, NY103 estudis
- Houston, TX76 estudis
- Los Angeles, CA61 estudis
- Boston, MA59 estudis
- St. Louis, MO46 estudis
- San Francisco, CA45 estudis
- Philadelphia, PA44 estudis
- Baltimore, MD43 estudis
- Nashville, TN42 estudis
- Seattle, WA42 estudis
- Washington, DC38 estudis
- Dallas, TX36 estudis
Altres estudis a Chicago
- Càncer de pulmó de cèl·lules no petites61 estudis
- Càncer de mama58 estudis
- Càncer (tots els tipus)51 estudis
- Càncer metastàtic45 estudis
- Obesitat41 estudis
- Càncer de pulmó41 estudis
- Càncer d'ovari36 estudis
- Ictus34 estudis
- Càncer colorrectal33 estudis
- Insuficiència cardíaca31 estudis
- Sobrepès28 estudis
- Carcinoma de cèl·lules escamoses de cap i coll26 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.